#

AbbVie

: 7
Eli Lillys earnings report, due out this week, could be one of the growth drivers for the S&P 500 healthcare sector / Photo: Michael Berlfein / Shutterstock.com
News·
Healthcare stocks have become a bet against AI. Should you buy them?
Data on the subcutaneous form of Skyrizi likely drove the rise in AbbVies stock / Photo: ChrisStock82 / Shutterstock.com
News·
Pharmaceutical companies benefited from the sell-off in the AI sector. Which stocks are nearing their all-time highs?
Analysts at Jefferies recommended that investors buy high-quality, “low-stress” stocks to weather the volatility associated with AI. Photo: lightman_pic/Shutterstock
News·
Jefferies Names 10 "Low-Stress" Stocks for the Summer to Weather AI Volatility
Galderma shares plummeted 6% on the Zurich Stock Exchange / Photo: Body Stock / Shutterstock
News·
Shares of pharmaceutical company Galderma plummeted: The U.S. has halted sales of a Botox generic
AbbVie Acquires Psoriasis Drug Developer for $10.9 Billion / Photo: AbbVie
News·
AbbVie will acquire a psoriasis drug developer for $11 billion. Its stock rose 47%.
According to sources cited by the Financial Times, the pharmaceutical company AbbVie is preparing to acquire Apogee for $11 billion / Photo: abbvie.scene7.com
News·
AbbVie is preparing to acquire a dermatitis drug developer for $11 billion — FT
The focus is on the release of the Consumer Price Index (CPI) data for December / Photo: jittawit21 / Shutterstock
News·
New York morning: focus on inflation and the start of the reporting season